通过TrialNet独特工作模式理解与预防1型糖尿病
1型糖尿病是由胰腺产胰岛素β细胞破坏所致的自身免疫病,呈连续进展过程。识别症状前早期阶段为预防试验提供条件。本文聚焦TrialNet这一国际临床试验联盟,其纵向生物样本库已超70,000份样本,综述由此产生的新生物标志物与机制见解,并指出通过临床试验与机制研究整合、临床医生与科学家参与及产业合作,TrialNet为理解这一迄今无法治愈的疾病和设计新治疗策略提供了独特工作模式。
要点
- 1型糖尿病为连续进展的自身免疫病,症状前可识别阶段为预防试验提供窗口。
- TrialNet为国际临床试验联盟,领导干预与预防研究并配套纵向生物采样。
- 其生物资源库超70,000份样本,已催生新生物标志物与机制见解。
核心结论
- 通过临床试验与机制研究整合、临床医生与科学家参与及产业合作,TrialNet为理解迄今无法治愈的1型糖尿病和设计新治疗策略提供了独特工作模式。
研究设计与样本
- 综述,聚焦1型糖尿病TrialNet国际临床试验联盟的纵向生物样本库(超70,000份样本)及由此产生的发现。
主要发现
- 1型糖尿病为自身免疫病,呈连续进展,症状前可识别阶段为预防试验提供条件。
- TrialNet纵向生物样本库已超70,000份样本,并催生新生物标志物与机制见解。
- TrialNet整合临床试验与机制研究,并开展产业合作。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Type 1 diabetes is an autoimmune disease arising from the destruction of pancreatic insulin-producing beta cells. The disease represents a continuum, progressing sequentially at variable rates through identifiable stages prior to the onset of symptoms, through diagnosis and into the critical periods that follow, culminating in a variable depth of beta cell depletion. The ability to identify the very earliest of these presymptomatic stages has provided a setting in which prevention strategies can be trialled, as well as furnishing an unprecedented opportunity to study disease evolution, including intrinsic and extrinsic initiators and drivers. This niche opportunity is occupied by Type 1 Diabetes TrialNet, an international consortium of clinical trial centres that leads the field in intervention and prevention studies, accompanied by deep longitudinal bio-sampling. In this review, we focus on discoveries arising from this unique bioresource, comprising more than 70,000 samples, and outline the processes and science that have led to new biomarkers and mechanistic insights, as well as identifying new challenges and opportunities. We conclude that via integration of clinical trials and mechanistic studies, drawing in clinicians and scientists and developing partnership with industry, TrialNet embodies an enviable and unique working model for understanding a disease that to date has no cure and for designing new therapeutic approaches.
引用
- Battaglia M, Anderson MS, Buckner JH, et al. Understanding and preventing type 1 diabetes through the unique working model of TrialNet. Diabetologia. 2017. PMID: 28770323. doi:10.1007/s00125-017-4384-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。